{
  "paper_id": "PMC9636712",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9636712/",
  "figures": {
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "High expression of ACE2 is associated with drug resistance in breast cancer patients. A The ACE2 expression profiles of breast cancer samples and normal tissues in the TCGA-BRCA and GTEx database. (Dot plot) Each dot represents the expression of a sample (*P < 0.05). B Western blot analysis showed the expression of ACE2 protein in normal breast cell line (MCF-10A) and breast cancer cell lines (MDA-468, MDA-231, T47D, MCF-7, BT-549, SK-BR-3, BT-474). The number below every lane represents the ratio of ACE2/β-actin expression in the Western blot assays. C Expression levels of ACE2 gene in breast cancer, colon colorectal cancer, lung cancer, kidney cancer and pancreatic cancer cell lines from the Cancer Cell Line Encyclopedia (CCLE). The vertical axis in the figure represents ACE2 expression, the horizontal axis is the cell lines, and the different colors represent the group of cell lines. D ACE2 expression levels in the plasma of all breast cancer patients (n = 111) and healthy controls (n = 20) were measured by ELISA (P = 4.7e−12). E The plasma levels of ACE2 in chemosensitive and insensitive breast cancer patients (P = 3.9e-06). (F) Comparison of ACE2 expression levels in breast cancer patients receiving and not receiving chemotherapy in METABRIC (***P < 0.001) and (G) TCGA-BRCA database (****P < 0.0001)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/63508d21a9a2/12967_2022_3716_Fig2_HTML.jpg"
    },
    "figure_5": {
      "figure_number": "Figure 5",
      "title": "Fig. 5.",
      "caption": "HIF-1α is directly involved in the regulation of chemotherapeutic drug-induced, ROS-mediated ACE2 expression. A Western blot and qRT-PCR analysis showed HIF-1α expression in four breast cancer cells after exposure to 0.05 µM EPI, 500 µM NAC, 0.05 µM EPI + 500 µM NAC for 72 h or 100 µM H2O2 for 4 h. B Western blotting analysis of ACE2 and HIF-1α expression in parental and resistant breast cancer cells cultured under normoxic or hypoxic (1% O2 for 24 h) conditions. The relative expression of proteins is quantified by grayscale analysis and is shown below the bands. C Knockdown of HIF-1α in MDA-468 cells or D inhibition of HIF-1α by YC-1 inhibitor blocked the EPI-induced elevation of ACE2 in breast cancer cells under normoxia or hypoxia. The relative expression of proteins is quantified by grayscale analysis and is shown below the bands. E Western blot analysis showed that both knockdown and inhibition of HIF-1α expression significantly decreased ACE2 expression in drug-resistant breast cancer cells (468/EPR cells). β-actin was used as an internal reference protein. F Western blot analysis showed no change in the protein level of HIF-1α after knockdown of ACE2 in 468/EPR cells and overexpression of ACE2 in MDA-468 cells. β-actin was used as a loading control",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig5",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_5.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/caaacb932858/12967_2022_3716_Fig5_HTML.jpg"
    },
    "figure_6": {
      "figure_number": "Figure 6",
      "title": "Fig. 6.",
      "caption": "ROS-dependent AKT activation mediates chemotherapeutic drug-induced elevation of ACE2 in breast cancer cells through regulation of HIF-1α. A Western blot analysis of the expression of AKT and p-AKT in MDA-468 cells treated with EPI, NAC, H2O2 or EPI + NAC. B Inhibition of AKT phosphorylation by MK2206 completely blocked the expression of ACE2 and HIF-1α in EPI-induced breast cancer cells. C Western blot and D qRT-PCR showed that the expression levels of HIF-1α and ACE2 were downregulated in resistant breast cancer cells after inhibition of AKT phosphorylation. The numbers below the bands refer to the intensity of the relative grayscale values. β-actin was also used as the internal reference for qRT-PCR analysis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig6",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_6.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/4bbd28060457/12967_2022_3716_Fig6_HTML.jpg"
    },
    "figure_7": {
      "figure_number": "Figure 7",
      "title": "Fig. 7.",
      "caption": "Knockdown of ACE2 reverses resistance to Epirubicin but promotes the proliferation of drug-resistant breast cancer cells. A Western blot and B qRT-PCR assays verified that ACE2 was successfully knocked down by three independent shRNA targeting ACE2 in 468/EPR cells. C Silencing ACE2 in 468/EPR cells significantly increased the sensitivity to EPI compared with shControl and wild-type cells. The IC50 assay was performed by using the CCK-8 based method. D Silencing ACE2 in 468/EPR cells significantly increased cell proliferative activity compared with shControl cells (****P < 0.0001). E Knockdown of ACE2 in 468/EPR cells remarkably increased the formation of cell colonies compared with shControl cells (****P < 0.0001). F EdU cell proliferation assay displayed that knockdown of ACE2 expression resulted in a significant increase in EdU positive rate, indicating higher cell proliferation ability. G Intracellular ROS levels were remarkably increased in ACE2 knockdown 468/EPR cells than in shControl cells. H Intracellular ROS levels were increased approximately 4-fold in 468/EPR-shACE2 cells treated with 0.05 µM EPI for 72 h compared to control cells. I Knockdown of ACE2 significantly increased the rate of EPI-induced apoptosis in 468/EPR cells compared with the control group. All data are shown as mean ± SD; *P < 0.05, *P < 0.01, ***P < 0.001, ****P < 0.0001, and ns P > 0.05 versus control",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig7",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_7.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/7fa5d5c34637/12967_2022_3716_Fig7_HTML.jpg"
    },
    "figure_8": {
      "figure_number": "Figure 8",
      "title": "Fig. 8.",
      "caption": "ACE2 is strongly positively correlated with breast cancer drug resistance genes (BRCA-DRGs). A The Venn diagram of common upregulated genes between four groups of drug-resistant cells and breast cancer drug-resistant genes defined by GeneCards. The barplot below Venn diagram shows the detailed number of each gene list. B Heatmap showing the correlation of genes expression in breast cancer drug resistance gene set. C The bubble plot summarizing the correlations between BRCA-DRGs and anticancer drugs. D Kaplan–Meier survival analysis of the signature (BRCA-DRGs) in TCGA-BRCA and (E) METABRIC databases. F Spearman correlation analysis of ACE2 expression and the signature (BRCA-DRGs). Scatter plot showed that the expression of ACE2 and the signature (BRCA-DRGs) was positively correlated in breast cancer drug-resistant cells (R = 0.858, P = 8.25e−08)",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig8",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_8.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/bd4378b332ef/12967_2022_3716_Fig8_HTML.jpg"
    },
    "figure_9": {
      "figure_number": "Figure 9",
      "title": "Fig. 9.",
      "caption": "Elevated ACE2 expression is a marker of poor prognosis in breast cancer patients receiving chemotherapy. A Waffle Chart of clinicopathological characteristics of breast cancer patients with high and low ACE2 expression. B Kaplan–Meier curves of the RFS and DMFS in BRCA patients receiving chemotherapy with high or low ACE2 expression (KM Plotter database). C Kaplan–Meier curves of the RFS and DMFS in ACE2 high and low expression groups in BRCA patients who did not receive chemotherapy (KM Plotter database). D Kaplan–Meier curves of the RFS and DMFS of systematically untreated BRCA with high or low ACE2 expression (KM Plotter database). E Kaplan–Meier survival analysis of OS in ACE2 high and low expression groups in the METABRIC cohort of breast cancer patients receiving chemotherapy and F breast cancer patients not receiving chemotherapy",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig9",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_9.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/630815f5723f/12967_2022_3716_Fig9_HTML.jpg"
    },
    "figure_10": {
      "figure_number": "Figure 10",
      "title": "Fig. 10.",
      "caption": "Schematic illustration of the relationship between ROS levels and ACE2 during chemotherapy in breast cancer cells. Left panel: In sensitive breast cancer cells with low ROS levels, ACE2 expression is relatively low; when the cells are stimulated by chemotherapeutic agents, ROS production is induced and phosphorylation of AKT is promoted, which in turn upregulates ACE2 expression by enhancing the expression of HIF-1α. Right panel: ACE2 is expressed at high levels in drug-resistant cells and maintains ROS homeostasis by inhibiting the overproduction of ROS. In drug-resistant cells with knockdown of ACE2, anticancer drugs induced a large increase in ROS levels, which induced apoptosis",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig10",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9636712/images/figure_10.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e870/9636712/e7d57258dd25/12967_2022_3716_Fig10_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "We first analyzed the RAW data of RNA-seq, which showed that drug-resistant cells had more reads mapping to exons of ACE2 than parental cells, suggesting that ACE2 may be upregulated in drug-resistant breast cancer cells (Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Indeed, as shown in boxplot, the mRNA expression of ACE2 was significantly upregulated in drug-resistant breast cancer cells (LogFC > 1, FDR < 0.05, Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Consistently, Western blot analysis also confirmed that ACE2 expression was substantially increased in the drug-resistant cells compared with parental cells (Fig. 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "We first analyzed the RAW data of RNA-seq, which showed that drug-resistant cells had more reads mapping to exons of ACE2 than parental cells, suggesting that ACE2 may be upregulated in drug-resistant breast cancer cells (Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Indeed, as shown in boxplot, the mRNA expression of ACE2 was significantly upregulated in drug-resistant breast cancer cells (LogFC > 1, FDR < 0.05, Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Consistently, Western blot analysis also confirmed that ACE2 expression was substantially increased in the drug-resistant cells compared with parental cells (Fig. 1C).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "Panel C",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Consistently, the result based on the analysis of the TCGA-BRCA and GTEx database showed that the expression of ACE2 in normal tissues was higher than that in breast cancer patients (Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 2B, breast cancer cells indeed expressed lower levels of ACE2 compared to normal breast cell MCF-10A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, as revealed by CCLE analysis, the expression level of ACE2 was lower in breast cancer cell lines than in other cancer cell lines, including colorectal, lung, and kidney cancers (Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 2D, the overall level of ACE2 in the plasma of breast cancer patients is still lower than that of healthy control.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Intriguingly, when classifying breast cancer patients according to their sensitivity to chemotherapy, we found that plasma ACE2 levels were significantly higher in chemotherapy-insensitive patients than in sensitive patients (Fig. 2E; Table 1, P < 0.0001).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In agreement with this finding, we also observed a similar association between upregulation of ACE2 levels and sensitivity to chemotherapy in breast cancer patients in the METABRIC and TCGA-BRCA database (Fig. 2F and G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Consistently, the result based on the analysis of the TCGA-BRCA and GTEx database showed that the expression of ACE2 in normal tissues was higher than that in breast cancer patients (Fig. 2A).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel A",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 2B, breast cancer cells indeed expressed lower levels of ACE2 compared to normal breast cell MCF-10A.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel B",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In addition, as revealed by CCLE analysis, the expression level of ACE2 was lower in breast cancer cell lines than in other cancer cell lines, including colorectal, lung, and kidney cancers (Fig. 2C).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        },
        {
          "figure_number": "Figure 2",
          "panel": "Panel C",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 2D, the overall level of ACE2 in the plasma of breast cancer patients is still lower than that of healthy control.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel D",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "Intriguingly, when classifying breast cancer patients according to their sensitivity to chemotherapy, we found that plasma ACE2 levels were significantly higher in chemotherapy-insensitive patients than in sensitive patients (Fig. 2E; Table 1, P < 0.0001).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel E",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "In agreement with this finding, we also observed a similar association between upregulation of ACE2 levels and sensitivity to chemotherapy in breast cancer patients in the METABRIC and TCGA-BRCA database (Fig. 2F and G).",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "Panel F",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 4A, drug treatment significantly increased the level of ROS in breast cancer cells, while ROS levels increased after the addition of H2O2 and decreased after NAC treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The results showed that the drug-induced increase in ROS levels was inhibited by the addition of NAC (Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Moreover, the expression of ACE2 in EPI-treated breast cancer cells was measured by qRT-PCR and western blotting in the presence or absence of NAC (Fig. 4B, C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 4A, drug treatment significantly increased the level of ROS in breast cancer cells, while ROS levels increased after the addition of H2O2 and decreased after NAC treatment.",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "The results showed that the drug-induced increase in ROS levels was inhibited by the addition of NAC (Fig. 4A).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        },
        {
          "figure_number": "Figure 4",
          "panel": "Panel A",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Moreover, the expression of ACE2 in EPI-treated breast cancer cells was measured by qRT-PCR and western blotting in the presence or absence of NAC (Fig. 4B, C).",
      "figure_references": [
        {
          "figure_number": "Figure 4",
          "panel": "Panel B",
          "figure_key": "figure_4"
        }
      ]
    },
    {
      "sentence": "Figure 5A showed that the mRNA and protein expression levels of HIF-1α were upregulated in four breast cancer cells after EPI treatment, while quenching of ROS with NAC counteracted the EPI-induced elevation of HIF-1α expression.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 5C, EPI-induced upregulation of ACE2 was suppressed by siHIF-1α under either normoxic or hypoxic conditions.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Consistently, the HIF-1α inhibitor YC-1 also blocked chemotherapy-induced expression of ACE2 (Fig. 5D).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Knockdown of HIF-1α expression with siRNA resulted in a decrease in ACE2 protein level in 468/EPR cells (Fig. 5E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Consistently, treatment of 468/EPR cells with YC-1 also reduced the expression of ACE2 (Fig. 5E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Nevertheless, the protein level of HIF-1α did not appear to be altered by overexpression of ACE2 in parental 468 cells and knockdown of ACE2 in resistant 468/EPR cells (Fig. 5F).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Figure 5A showed that the mRNA and protein expression levels of HIF-1α were upregulated in four breast cancer cells after EPI treatment, while quenching of ROS with NAC counteracted the EPI-induced elevation of HIF-1α expression.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel A",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 5C, EPI-induced upregulation of ACE2 was suppressed by siHIF-1α under either normoxic or hypoxic conditions.",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel C",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Consistently, the HIF-1α inhibitor YC-1 also blocked chemotherapy-induced expression of ACE2 (Fig. 5D).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel D",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Knockdown of HIF-1α expression with siRNA resulted in a decrease in ACE2 protein level in 468/EPR cells (Fig. 5E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Consistently, treatment of 468/EPR cells with YC-1 also reduced the expression of ACE2 (Fig. 5E).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel E",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "Nevertheless, the protein level of HIF-1α did not appear to be altered by overexpression of ACE2 in parental 468 cells and knockdown of ACE2 in resistant 468/EPR cells (Fig. 5F).",
      "figure_references": [
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        },
        {
          "figure_number": "Figure 5",
          "panel": "Panel F",
          "figure_key": "figure_5"
        }
      ]
    },
    {
      "sentence": "As expected, increased levels of phospho-AKT were detected after EPI treatment, whereas the addition of the ROS scavenger NAC counteracted the EPI-induced increase in AKT phosphorylation (Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 6B, MK-2206 significantly suppressed EPI-induced AKT phosphorylation and completely inhibited EPI-induced expression of HIF-1α and ACE2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 6C and D, inhibition of AKT phosphorylation reduced the expression of HIF-1α and ACE2 at the protein and mRNA levels.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As expected, increased levels of phospho-AKT were detected after EPI treatment, whereas the addition of the ROS scavenger NAC counteracted the EPI-induced increase in AKT phosphorylation (Fig. 6A).",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        },
        {
          "figure_number": "Figure 6",
          "panel": "Panel A",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 6B, MK-2206 significantly suppressed EPI-induced AKT phosphorylation and completely inhibited EPI-induced expression of HIF-1α and ACE2.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel B",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 6C and D, inhibition of AKT phosphorylation reduced the expression of HIF-1α and ACE2 at the protein and mRNA levels.",
      "figure_references": [
        {
          "figure_number": "Figure 6",
          "panel": "Panel C",
          "figure_key": "figure_6"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 7A and B, Western blot and qRT-PCR analysis showed that ACE2 expression was substantially reduced in ACE2 shRNA-infected cells compared with that of control shRNA-infected cells.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 7C and Table 2, the survival rate of resistant cells exposed to EPI was decreased after ACE2 knockdown, and the IC50 value of EPI was significantly reduced in ACE2-silenced cells compared with control cells.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "By contrast, CCK8-based assay showed that ACE2 silencing significantly increased the proliferative activity of resistant cells (Fig. 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, 468/EPR-shACE2 cells also showed remarkably increased colony-forming capacity in vitro compared with control cells (Fig. 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "EdU staining also confirmed that decreased expression of ACE2 significantly increased the cell proliferation index (Fig. 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Interestingly, knockdown of ACE2 resulted in an approximately 2-fold increase in intracellular ROS levels in 468/EPR cells compared to control cells (Fig. 7G).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Moreover, ROS levels were increased approximately 4-fold in 468/EPR-shACE2 cells treated with 0.05 µM EPI for 72 h compared to control cells (Fig. 7H).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, Annexin-V/PI staining assay displayed that the apoptosis rate of 468/EPR-shACE2 cells was significantly increased after 3 days of EPI treatment compared with the controls (Fig. 7I).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 7A and B, Western blot and qRT-PCR analysis showed that ACE2 expression was substantially reduced in ACE2 shRNA-infected cells compared with that of control shRNA-infected cells.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel A",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 7C and Table 2, the survival rate of resistant cells exposed to EPI was decreased after ACE2 knockdown, and the IC50 value of EPI was significantly reduced in ACE2-silenced cells compared with control cells.",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel C",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "By contrast, CCK8-based assay showed that ACE2 silencing significantly increased the proliferative activity of resistant cells (Fig. 7D).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel D",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Similarly, 468/EPR-shACE2 cells also showed remarkably increased colony-forming capacity in vitro compared with control cells (Fig. 7E).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel E",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "EdU staining also confirmed that decreased expression of ACE2 significantly increased the cell proliferation index (Fig. 7F).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel F",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Interestingly, knockdown of ACE2 resulted in an approximately 2-fold increase in intracellular ROS levels in 468/EPR cells compared to control cells (Fig. 7G).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel G",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Moreover, ROS levels were increased approximately 4-fold in 468/EPR-shACE2 cells treated with 0.05 µM EPI for 72 h compared to control cells (Fig. 7H).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel H",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "Furthermore, Annexin-V/PI staining assay displayed that the apoptosis rate of 468/EPR-shACE2 cells was significantly increased after 3 days of EPI treatment compared with the controls (Fig. 7I).",
      "figure_references": [
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        },
        {
          "figure_number": "Figure 7",
          "panel": "Panel I",
          "figure_key": "figure_7"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 8A, a 28 genes signature (named as BRCA-DRGs, Table 3) was identified by combined analysis of the upregulated genes (LogFC > 1 and FDR < 0.05) in the four groups of drug-resistant/parental RNA-Seq data and drug-resistant genes defined by GeneCards.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel A",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Expectedly, a strong positive correlation pattern was observed among these genes in our RNA-sequencing results of the four drug-resistant/parental cells, indicating that these genes are closely interconnected in drug-resistant cells (Fig. 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 8C, most of these genes were positively correlated with increased resistance of cancer cells to anticancer drugs, indicating that our constructed BRCA-DRGs could well predict the sensitivity of cancer cells to drugs.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel C",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Moreover, survival analysis based on TCGA-BRCA and METABRIC database further showed that patients with high expression of BRCA-DRGs had poorer overall survival time (Fig. 8D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel D",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Notably, we also identified a strong positive correlation between ACE2 and BRCA-DRGs (R = 0.858, P = 8.25e−08) (Fig. 8F), indicating that ACE2 may be involved in regulating drug resistance in breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 8A, a 28 genes signature (named as BRCA-DRGs, Table 3) was identified by combined analysis of the upregulated genes (LogFC > 1 and FDR < 0.05) in the four groups of drug-resistant/parental RNA-Seq data and drug-resistant genes defined by GeneCards.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel A",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Expectedly, a strong positive correlation pattern was observed among these genes in our RNA-sequencing results of the four drug-resistant/parental cells, indicating that these genes are closely interconnected in drug-resistant cells (Fig. 8B).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel B",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 8C, most of these genes were positively correlated with increased resistance of cancer cells to anticancer drugs, indicating that our constructed BRCA-DRGs could well predict the sensitivity of cancer cells to drugs.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel C",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Moreover, survival analysis based on TCGA-BRCA and METABRIC database further showed that patients with high expression of BRCA-DRGs had poorer overall survival time (Fig. 8D and E).",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel D",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Notably, we also identified a strong positive correlation between ACE2 and BRCA-DRGs (R = 0.858, P = 8.25e−08) (Fig. 8F), indicating that ACE2 may be involved in regulating drug resistance in breast cancer.",
      "figure_references": [
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        },
        {
          "figure_number": "Figure 8",
          "panel": "Panel F",
          "figure_key": "figure_8"
        }
      ]
    },
    {
      "sentence": "Waffle Chart was generated based on prognostic parameters and ACE2 expression (Fig. 9A).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 9B, among breast cancer patients receiving chemotherapy, both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were significantly lower in patients with high ACE2 expression than in those with low expression.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel B",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "However, there was no significant association between ACE2 expression and survival in breast cancer patients who did not receive chemotherapy and were systematically untreated (Fig. 9C, D).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel C",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 9E, in breast cancer patients receiving chemotherapy, high ACE2 expression was associated with poorer overall survival, whereas ACE2 expression was not significantly associated with overall survival in patients who did not receive chemotherapy.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel E",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "Waffle Chart was generated based on prognostic parameters and ACE2 expression (Fig. 9A).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        },
        {
          "figure_number": "Figure 9",
          "panel": "Panel A",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 9B, among breast cancer patients receiving chemotherapy, both recurrence-free survival (RFS) and distant metastasis-free survival (DMFS) were significantly lower in patients with high ACE2 expression than in those with low expression.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel B",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "However, there was no significant association between ACE2 expression and survival in breast cancer patients who did not receive chemotherapy and were systematically untreated (Fig. 9C, D).",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel C",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "As shown in Fig. 9E, in breast cancer patients receiving chemotherapy, high ACE2 expression was associated with poorer overall survival, whereas ACE2 expression was not significantly associated with overall survival in patients who did not receive chemotherapy.",
      "figure_references": [
        {
          "figure_number": "Figure 9",
          "panel": "Panel E",
          "figure_key": "figure_9"
        }
      ]
    },
    {
      "sentence": "As illustrated in Fig. 10, we demonstrate that ACE2 expression is relatively low in breast cancer cells, but its expression increases specifically and rapidly after exposure to anticancer drugs, and stabilizes at a high level after acquisition of drug resistance.",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    },
    {
      "sentence": "As illustrated in Fig. 10, we demonstrate that ACE2 expression is relatively low in breast cancer cells, but its expression increases specifically and rapidly after exposure to anticancer drugs, and stabilizes at a high level after acquisition of drug resistance.",
      "figure_references": [
        {
          "figure_number": "Figure 10",
          "panel": "",
          "figure_key": "figure_10"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 7,
    "claims_count": 78,
    "images_downloaded": 7,
    "tables_filtered": 27
  }
}